Alphabet's Verily is seeking approval from the Environmental Protection Agency to release millions of male mosquitoes in California and Florida.
This initiative represents a significant shift in public health strategy, moving from chemical pesticide reliance toward biological population control to prevent the spread of infectious diseases.
The request, filed this month, is part of a disease-control program called "Debug." Verily intends to release male mosquitoes infected with Wolbachia bacteria [1]. These specific mosquitoes are designed to suppress the populations of disease-carrying species that transmit illnesses such as dengue and Zika [4].
There are conflicting reports regarding the exact scale of the release. The Guardian said that Verily is seeking to release up to 32 million mosquitoes [1]. However, The Next Web said the figure is 64 million [2], while The Independent said the amount is more than 30 million [3].
Wolbachia is a naturally occurring bacteria. When male mosquitoes carrying the bacteria mate with wild females, the resulting eggs typically do not hatch. Because the program only releases male mosquitoes, the initiative does not increase the number of biting insects in the target areas, since only female mosquitoes bite, but instead aims to crash the local population over time.
The program targets regions in the U.S. where the risk of tropical disease transmission is increasing due to changing environmental conditions. By reducing the number of viable mosquitoes, the company aims to lower the transmission rates of the targeted viruses [4].
Verily has not provided a specific timeline for the releases, as the project remains pending EPA approval [1].
“Alphabet's Verily is seeking approval from the Environmental Protection Agency to release millions of male mosquitoes.”
The use of Wolbachia-infected insects marks a transition toward 'biocontrol' in the U.S., leveraging synthetic biology to manage public health risks. If approved, this deployment would validate a scalable model for suppressing vector-borne diseases without the ecological footprint of broad-spectrum insecticides, though it raises long-term questions about the impact of large-scale biological interventions on local ecosystems.
